These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32992012)

  • 1. HEPCARE EUROPE- A case study of a service innovation project aiming at improving the elimination of HCV in vulnerable populations in four European cities.
    Avramovic G; Reilly M; Cullen W; Macías J; McCombe G; McHugh T; Oprea C; Story A; Surey J; Sabin C; Bivegete S; Vickerman P; Walker J; Ward Z; Lambert JS
    Int J Infect Dis; 2020 Dec; 101():374-379. PubMed ID: 32992012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring and understanding HCV patient journeys- HEPCARE Europe project.
    Glaspy S; Avramovic G; McHugh T; Oprea C; Surey J; Ianache I; Macías J; Story A; Cullen W; Lambert JS
    BMC Infect Dis; 2021 Mar; 21(1):239. PubMed ID: 33673828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
    BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    Papatheodoridis GV; Hatzakis A; Cholongitas E; Baptista-Leite R; Baskozos I; Chhatwal J; Colombo M; Cortez-Pinto H; Craxi A; Goldberg D; Gore C; Kautz A; Lazarus JV; Mendão L; Peck-Radosavljevic M; Razavi H; Schatz E; Tözün N; van Damme P; Wedemeyer H; Yazdanpanah Y; Zuure F; Manns MP
    J Viral Hepat; 2018 Mar; 25 Suppl 1():6-17. PubMed ID: 29508946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HepCare Ireland-a service innovation project.
    Connolly SP; Avramovic G; Cullen W; McHugh T; O'Connor E; Mc Combe G; Crowley D; Naughton AM; Horan A; Lambert JS
    Ir J Med Sci; 2021 May; 190(2):587-595. PubMed ID: 32761548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocol.
    Swan D; Cullen W; Macias J; Oprea C; Story A; Surey J; Vickerman P; Lambert JS
    Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):303-314. PubMed ID: 29300496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
    Fadnes LT; Aas CF; Vold JH; Ohldieck C; Leiva RA; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
    BMC Infect Dis; 2019 Nov; 19(1):943. PubMed ID: 31703669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
    Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HepCare Europe-A service innovation project. HepCheck: Characteristics of the patient population with active infection as defined by HCV RNA.
    Avramovic G; Oprea C; Surey J; Story A; Macías J; Cullen W; Iglesias M; Mc Hugh T; Crowley D; Naughton AM; Horan A; Ianache I; Lazar S; Popa I; Menezes D; Lambert JS
    Int J Infect Dis; 2020 Feb; 91():246-251. PubMed ID: 31785401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
    Martin NK; Boerekamps A; Hill AM; Rijnders BJA
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25062. PubMed ID: 29633560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HepCare Europe: a service innovation project. HepCheck: enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening. A prospective multisite feasibility study.
    Barror S; Avramovic G; Oprea C; Surey J; Story A; Macías J; Cullen W; Crowley D; Horan A; Naughton AM; Iglesias M; Ianache I; Lazar S; Popa I; McHugh T; Menezes D; Tinago W; Lambert JS
    J Antimicrob Chemother; 2019 Nov; 74(Suppl 5):v39-v46. PubMed ID: 31782499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Guide to the Economics of Hepatitis C Virus Cure in 2017.
    Linas BP; Nolen S
    Infect Dis Clin North Am; 2018 Jun; 32(2):447-459. PubMed ID: 29778265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
    Benzaken AS; Girade R; Catapan E; Pereira GFM; Almeida EC; Vivaldini S; Fernandes N; Razavi H; Schmelzer J; Ferraz ML; Ferreira PRA; Pessoa MG; Martinelli A; Souto FJD; Walsh N; Mendes-Correa MC
    Braz J Infect Dis; 2019; 23(3):182-190. PubMed ID: 31145876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
    Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
    Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).
    Janjua NZ; Kuo M; Yu A; Alvarez M; Wong S; Cook D; Wong J; Grebely J; Butt ZA; Samji H; Ramji A; Tyndall M; Krajden M
    EBioMedicine; 2016 Oct; 12():189-195. PubMed ID: 27596150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial.
    Pericot-Valverde I; Heo M; Akiyama MJ; Norton BL; Agyemang L; Niu J; Litwin AH
    BMC Infect Dis; 2020 Dec; 20(1):928. PubMed ID: 33276738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
    Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
    Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.